Nordic Nanovector to present at the Swiss-Scandinavian Bio-Business seminar on 10 February 2016
Oslo, Norway, 5 February 2016
Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialization of novel targeted therapeutics in haematology and oncology, announces that its CFO Tone Kvåle will present at the Swiss-Scandinavian Bio-Business seminar in Zurich, Switzerland on 10 February 2016. The slides of the presentation given will be available on the Nordic Nanovector website in the section:
Investor Relations/Reports and Presentations/Presentations/2016.
###
For further information, please contact:
Tone Kvåle, Chief Financial Officer
tkvale@nordicnanovector.com
Cell: +47 91 51 95 76
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
nordicnanovector@citigatedr.co.uk
Tel: +44 207 282 2948/+44 207 282 2949
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionuclide (lutetium- 177). It has shown promising efficacy and a favourable safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
Tags: